ArticleFrontiers in endocrinology2022

JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.

Partha Das et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.